Frontier Pharma Report: Schizophrenia Markets 2018 - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 8, 2018--The “Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms” report has been added to ResearchAndMarkets.com’s offering.
″“Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms”″; First-in-class products have the greatest potential in terms of development and commercial prospects. In line with the overall pipeline, first-in-class innovation is dominated by products acting on neuromodulator targets with the strongest representation in the Discovery and Preclinical stages of development.
The schizophrenia pipeline is relatively small, given the large patient population and well-defined unmet needs, with a total of 160 products in active development. This is indicative of a low level of R&D funding and investment, most likely due to a poor understanding of the underlying mechanisms of the disease, which acts as a strong barrier to the development of effective pharmaceutical products.
Reflecting the situation in the market, the overwhelming majority of these products are small molecules, with a small but notable portion of the pipeline consisting of other molecule types such as cell therapies, peptides and vaccines - none of which are currently present in the schizophrenia market.
ScopeInnovation within schizophrenia is relatively small. What are the unmet needs across this therapy area? There are 160 products in the pipeline for schizophrenia. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class? Although the first-in-class pipeline is small in comparison with other CNS-related disorders, it is relatively diverse, with numerous molecular targets. Which first-in-class targets have been identified as most promising for schizophrenia? A total of 77 licensing deals and 44 development deals related to schizophrenia have been completed since 2006. Does schizophrenia attract high-value deals? Which first-in-class products have no prior deal involvement?
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Schizophrenia Pathophysiology and Innovation Alignment
7 First-in-Class Molecular Target Evaluation
8 Deals and Strategic Consolidations
For more information about this report visit https://www.researchandmarkets.com/research/6vf5f4/frontier_pharma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180608005591/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Schizophrenia Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/08/2018 01:24 PM/DISC: 06/08/2018 01:24 PM